BioHarvest Sciences Inc Dossier
Qualitative Analysis
Business overview
BioHarvest Sciences Inc. (NASDAQ: BHST; FSE: 8MV0) is a global leader in Botanical Synthesis and plant cell biology. The company utilizes its patented Bio-Plant CELLicitation™ technology platform to grow active plant-based compounds in industrial-scale bioreactors without the need to grow the underlying plant itself. This proprietary process ensures high consistency, purity, and solubility while avoiding the environmental footprint of traditional agriculture. BioHarvest operates through two primary business verticals: a Contract Development and Manufacturing Organization (CDMO) division serving corporate clients seeking complex plant-based molecules, and a Direct-to-Consumer (D2C) division that markets proprietary nutraceutical health and wellness products, including its flagship red grape cell supplement, VINIA.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A strategic framework enacted in Q1 2026 to optimize performance across the company's two core business engines: the Direct-to-Consumer (D2C) product division and the Contract Development and Manufacturing Organization (CDMO) division. This included a leadership transition where Co-Founder Dr. Zaki Rakib assumed the CEO role to integrate R&D, manufacturing, and operations under the CDMO, while former CEO Ilan Sobel joined the Board to focus on D2C growth.
Expected impact: Accelerating commercial scalability for CDMO partners, deepening platform capabilities, and driving long-term royalty-driven and product-based revenue streams.
Pivoting the majority of the D2C marketing budget from traditional television advertising to digital marketing channels. This shift targets a younger consumer demographic with high disposable income and aims to scale the newly launched VINIA Blood Flow Hydration product.
Expected impact: Improving the ratio of customer lifetime value (LTV) to customer acquisition cost (CAC) and driving sequential quarter-over-quarter D2C revenue growth.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
In May 2026, the companies expanded their initial 2024 collaboration to include multiple plant-based sweetener molecules. The partnership leverages BioHarvest's Botanical Synthesis platform to develop scalable, non-GMO sugar substitutes, strengthening Tate & Lyle's sweetening solutions portfolio.
Terms: Specific financial terms of the expansion were not disclosed, but the program aims to build a flexible toolkit of sweetening options for global food and beverage manufacturers.
Entered in October 2025 to develop and commercialize saffron-derived botanical compounds using BioHarvest's Botanical Synthesis platform. The partnership successfully completed Stage 1 in May 2026, establishing a stable saffron cell bank.
Terms: BioHarvest retains a 25% ownership stake in the successfully developed saffron compositions, with Saffron Tech owning the remaining 75%.